Recent advances in the understanding of immune-mediated nephrotic syndrome: diagnostic and prognostic implications

References

• van Paassen P, van Breda Vriesman PJ, van Rie H, et al. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004;66(3):909-13
   PubMedGoogle Scholar
• Cattran D. Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 2005;16(5):1188-94
   PubMed Web of Science ®Google Scholar
• Couser WG, Steinmuller DR, Stilmant MM, et al. Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest 1978;62(6):1275-87
   PubMedGoogle Scholar
• Couser WG, Salant DJ. In situ immune complex formation and glomerular injury. Kidney Int 1980;17(1):1-13
   PubMedGoogle Scholar
• Topham PS, Haydar SA, Kuphal R, et al. Complement-mediated injury reversibly disrupts glomerular epithelial cell actin microfilaments and focal adhesions. Kidney Int 1999;55(5):1763-75
   PubMed Web of Science ®Google Scholar
• Saran AM, Yuan H, Takeuchi E, et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003;64(6):2072-8
   PubMed Web of Science ®Google Scholar
• Beck LHJr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361(1):11-21
   PubMed Web of Science ®Google Scholar
• Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011;364(7):616-26
   PubMed Web of Science ®Google Scholar
• Kao L, Lam V, Waldman M, et al. Identification of the immunodominant epitope region in phospholipase a2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol 2015;26(2):291-301
   PubMed Web of Science ®Google Scholar
• Coenen MJ, Hofstra JM, Debiec H, et al. Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 2013;24(4):677-83
   PubMed Web of Science ®Google Scholar
• Lv J, Hou W, Zhou X, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 2013;24(8):1323-9
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A(2)-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011;26(8):2526-32
   PubMed Web of Science ®Google Scholar
• Dahnrich C, Komorowski L, Probst C, et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013;421:213-18
   PubMed Web of Science ®Google Scholar
• Timmermans SAMEG, Damoiseaux JG, Heerings-Rewinkel PT, et al. Evaluation of anti-PLA2R1 as measured by a novel ELISA in patients with idiopathic membranous nephropathy: a cohort study. Am J Clin Pathol 2014;142(1):29-34
   PubMed Web of Science ®Google Scholar
• Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011;364(7):689-90
   PubMed Web of Science ®Google Scholar
• Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 2013;28(7):1839-44
   PubMed Web of Science ®Google Scholar
• Qin W, Beck LHJr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011;22(6):1137-43
   PubMed Web of Science ®Google Scholar
• Larsen CP, Messias NC, Silva FG, et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013;26(5):709-15
   PubMed Web of Science ®Google Scholar
• Hoxha E, Kneissler U, Stege G, et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012;82(7):797-804
   PubMed Web of Science ®Google Scholar
• Murtas C, Bruschi M, Candiano G, et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012;7(9):1394-400
   PubMed Web of Science ®Google Scholar
• Tomas NM, Beck LHJr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7a in idiopathic membranous nephropathy. N Engl J Med 2014;371(24):2277-87
   PubMed Web of Science ®Google Scholar
• Noel LH, Zanetti M, Droz D, et al. Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979;66(1):82-90
   PubMed Web of Science ®Google Scholar
• van den Brand JA, Hofstra JM, Wetzels JF. Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6(12):2846-53
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48(5):1600-4
   PubMed Web of Science ®Google Scholar
• Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18(6):1899-904
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 7: idiopathic membranous nephropathy. Kidney Int Suppl 2012;2(2):186-97
   Web of Science ®Google Scholar
• Hofstra JM, Beck LHJr, Beck DM, et al. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6(6):1286-91
   PubMed Web of Science ®Google Scholar
• Kanigicherla D, Gummadova J, McKenzie EA, et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013;83(5):940-8
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Debiec H, Short CD, et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23(10):1735-43
   PubMed Web of Science ®Google Scholar
• Hoxha E, Harendza S, Pinnschmidt H, et al. M-type phospholipase a2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol 2014;9(11):1883-90
   PubMed Web of Science ®Google Scholar
• Beck LHJr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22(8):1543-50
   PubMed Web of Science ®Google Scholar
• Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014;25(6):1357-66
   PubMed Web of Science ®Google Scholar
• Bech AP, Hofstra JM, Brenchley PE, et al. Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2014;9(8):1386-92
   PubMed Web of Science ®Google Scholar
• Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013;381(9868):744-51
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Chianca A, et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23(8):1416-25
   PubMed Web of Science ®Google Scholar
• Brown EJ, Pollak MR, Barua M. Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing. Kidney Int 2014;85(5):1030-8
   PubMed Web of Science ®Google Scholar
• Kidney Disease: improving Glonal Outcomes (KDIGO) Glomerulonephritis Work Group. Chapter 6: idiopathic focal segmental glomerulosclerosis in adults. Kidney Int Suppl 2012;2(2):181-5
   Google Scholar
• Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996;334(14):878-83
   PubMed Web of Science ®Google Scholar
• Sharma M, Sharma R, McCarthy ET, Savin VJ. “The FSGS factor:” enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol 1999;10(3):552-61
   PubMedGoogle Scholar
• Kemper MJ, Wolf G, Müller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001;344(5):386-7
   PubMedGoogle Scholar
• Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013;61(2):352
   PubMedGoogle Scholar
• Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17(8):952-60
   PubMed Web of Science ®Google Scholar
• Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012;23(12):2051-9
   PubMed Web of Science ®Google Scholar
• Meijers B, Maas RJ, Sprangers B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 2014;85(3):636-40
   PubMed Web of Science ®Google Scholar
• Bock ME, Price HE, Gallon L, et al. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013;8(8):1304-11
   PubMedGoogle Scholar
• Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol 2007;2(3):529-42
   PubMedGoogle Scholar
• Garin EH, Diaz LN, Mu W, et al. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol 2009;20(2):260-6
   PubMed Web of Science ®Google Scholar
• Garin EH, Mu W, Arthur JM, et al. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int 2010;78(3):296-302
   PubMed Web of Science ®Google Scholar
• Eto N, Wada T, Inagi R, et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007;72(4):455-63
   PubMedGoogle Scholar
• Garin EH, Reiser J, Cara-Fuentes G, et al. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis. Pediatr Nephrol 2015;30(3):469-77
   PubMed Web of Science ®Google Scholar
• Sayed RH, Gilbertson JA, Hutt DF, et al. Misdiagnosing renal amyloidosis as minimal change disease. Nephrol Dial Transplant 2014;29(11):2120-6
   PubMedGoogle Scholar
• Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013;8(9):1515-23
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32(1):45-59
   PubMed Web of Science ®Google Scholar
• Leung N, Nasr SH, Sethi S. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing. Blood 2012;120(16):3206-13
   PubMed Web of Science ®Google Scholar
• Hilhorst M, van Paassen P, van Breda Vriesman P, et al. Immune complexes in acute adult-onset Henoch-Schonlein nephritis. Nephrol Dial Transplant 2011;26(12):3960-7
   PubMedGoogle Scholar
• Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol 1995;100(3):470-4
   PubMedGoogle Scholar
• Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 2009;119(6):1668-77
   PubMed Web of Science ®Google Scholar
• Novak J, Moldoveanu Z, Renfrow MB, et al. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells. Contrib Nephrol 2007;157:134-8
   PubMedGoogle Scholar
• Gutierrez E, Zamora I, Ballarin JA, et al. Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol 2012;23(10):1753-60
   PubMed Web of Science ®Google Scholar
• Szeto CC, Lai FM, To KF, et al. The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001;110(6):434-7
   PubMed Web of Science ®Google Scholar
• Shen P, He L, Huang D. Clinical course and prognostic factors of clinical early IgA nephropathy. Neth J Med 2008;66(6):242-7
   PubMed Web of Science ®Google Scholar
• Radford MGJr, Donadio JVJr, Bergstralh EJ, et al. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol 1997;8(2):199-207
   PubMed Web of Science ®Google Scholar
• Camilla R, Suzuki H, Dapra V, et al. Oxidative stress and galactose-deficient IgA1 as markers of progression in IgA nephropathy. Clin J Am Soc Nephrol 2011;6(8):1903-11
   PubMedGoogle Scholar
• Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 2012;82(7):790-6
   PubMed Web of Science ®Google Scholar
• Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 2012;23(9):1579-87
   PubMed Web of Science ®Google Scholar
• Liu LL, Jiang Y, Wang LN, et al. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig)A nephropathy. Clin Exp Immunol 2012;169(2):148-55
   PubMed Web of Science ®Google Scholar
• Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006;17(6):1724-34
   PubMed Web of Science ®Google Scholar
• Liu LL, Liu N, Chen Y, et al. Glomerular mannose-binding lectin deposition is a useful prognostic predictor in immunoglobulin A nephropathy. Clin Exp Immunol 2013;174(1):152-60
   PubMed Web of Science ®Google Scholar
• Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med 2012;366(12):1119-31
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328(7):465-70
   PubMed Web of Science ®Google Scholar
• Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010;5(5):770-82
   PubMedGoogle Scholar
• Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004;65(1):85-96
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120(22):4292-5
   PubMed Web of Science ®Google Scholar
• Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009;20(9):2055-64
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW. Membranoproliferative glomerulonephritis: the times they are a-changin’. Clin Exp Nephrol 2014;18(1):1-3
   PubMedGoogle Scholar
• Hiramatsu R, Hoshino J, Suwabe T, et al. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol 2014;18(1):88-94
   PubMed Web of Science ®Google Scholar
• Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33(6):355-74
   PubMed Web of Science ®Google Scholar
• Tervaert JW, Van Paassen P, Damoiseaux J. Type II cryoglobulinemia is not associated with hepatitis C infection: the Dutch experience. Ann N Y Acad Sci 2007;1107:251-8
   PubMedGoogle Scholar
• Vermeersch P, Gijbels K, Marien G, et al. A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins. Clin Chem 2008;54(1):39-43
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Cohen Tervaert JW. Diagnostics and treatment of cryoglobulinaemia: it takes two to tango. Clin Rev Allergy Immunol 2014;47(3):299-310
   PubMedGoogle Scholar
• Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012;27(12):4288-94
   PubMedGoogle Scholar
• Walport MJ. Complement. First of two parts. N Engl J Med 2001;344(14):1058-66
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344(15):1140-4
   PubMed Web of Science ®Google Scholar
• Servais A, Noel LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82(4):454-64
   PubMed Web of Science ®Google Scholar
• Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010;120(10):3702-12
   PubMedGoogle Scholar
• Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010;376(9743):794-801
   PubMed Web of Science ®Google Scholar
• Paixao-Cavalcante D, Lopez-Trascasa M, Skattum L, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int 2012;82(10):1084-92
   PubMed Web of Science ®Google Scholar
• Zhang Y, Meyer NC, Wang K, et al. Causes of alternative pathway dysregulation in dense deposit disease. Clin J Am Soc Nephrol 2012;7(2):265-74
   PubMedGoogle Scholar
• Bridoux F, Desport E, Fremeaux-Bacchi V, et al. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin J Am Soc Nephrol 2011;6(9):2165-74
   PubMed Web of Science ®Google Scholar
• Pickering MC, D’Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84(6):1079-89
   PubMed Web of Science ®Google Scholar
• George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371(7):654-66
   PubMed Web of Science ®Google Scholar
• Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007;204(6):1249-56
   PubMedGoogle Scholar
• Hilhorst M, Wilde B, van Breda Vriesman P, et al. Estimating renal survival using the ANCA-associated GN classification. J Am Soc Nephrol 2013;24(9):1371-5
   PubMedGoogle Scholar
• Hagen EC, Daha MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53(3):743-53
   PubMed Web of Science ®Google Scholar
• Cohen Tervaert JW, Damoiseaux J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 2012;43(3):211-19
   PubMedGoogle Scholar
• Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the “Euro-Lupus Project”. Autoimmun Rev 2006;5(3):180-6
   PubMedGoogle Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15(2):241-50
   PubMed Web of Science ®Google Scholar
• Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983;24(3):377-85
   PubMedGoogle Scholar
• Damoiseaux JG, Tervaert JW. From ANA to ENA: how to proceed? Autoimmun Rev 2006;5(1):10-17
   PubMedGoogle Scholar
• Tervaert JW, Kallenberg CG. Clinical immunology - Autoimmunity in the Netherlands. Immunol Lett 2014;162(2PB):134-40
   PubMedGoogle Scholar
• Trouw LA, Groeneveld TW, Seelen MA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004;114(5):679-88
   PubMedGoogle Scholar
• Yang XW, Tan Y, Yu F, et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant 2012;27(9):3552-9
   PubMed Web of Science ®Google Scholar